Selected Reports from
The ICAAC Conference in Toronto:
Written by Jules Levin & others
Toronto, Canada, September 2000
Update Summary on Therapy
Interruptions (12/18/2000)
Highlights from 40th
ICAAC
Written
for NATAP by Harvey S.
Bartnof, MD,
Staff Physician at AVERI, AIDS Virus Education and Research
Institute, San Francisco, California
Late Breaker Report
Abacavir
Interruptions; Intermittent Therapy in SIV; IL-2 & Viral Load
Drug
Interactions Report
Summary
of Pharmacokinetics Reports at ICAAC
Live From
Toronto
written by Jules Levin
Report
15
Report from the 40th ICAAC
Written for NATAP by Robert Murphy, MD,
Northwestern University in Chicago, and ACTG researcher
1) Simplificationî Studies:
Switching from Protease Inhibitor-Based Therapies
2) New Drugs
Report
13
DIRECT
Study: 800/100 mg Indinavir-Ritonavir BID +abacavir/3TC
Report
12
ICAAC
Updates
Report
11
ABT-378
(Kaletra): 96 Week Update in Treatment-Naive
Report
9
BMS-232632: once a day protease
inhibitor in early human development
Report
8
Treatment Interruption
& Affect on CD4 & Viral Load
Report
7
Efaviranz
+ d4T/3TC: 84-week data; open-label, single arm study
Report
6
Higher
Dosing Regimen Used of ABT-378/r--
-ABT-378/r
(Kaletra) + Efavirenz: 24 week study results in multiple PI Experienced
-ABT-378/r & Efavirenz
Interactions